U.S. Senator Bernie Sanders fires off at CEO of Novo Nordisk

The Senate Health Committee held a hearing on the high prices of Ozempic and Wegovy, questioning Novo Nordisk's CEO, Lars Jorgensen. The drugs are significantly more expensive in the U.S. compared to other countries. Jorgensen defended the prices, citing insurance companies' role in cost determination. The hearing also discussed the impact of inflation and demand on prices, and the potential for expanded coverage if list prices are lowered.

What new insight or understanding did you gain from this video?